MXPA05006042A - Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores. - Google Patents

Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.

Info

Publication number
MXPA05006042A
MXPA05006042A MXPA05006042A MXPA05006042A MXPA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A
Authority
MX
Mexico
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
MXPA05006042A
Other languages
English (en)
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of MXPA05006042A publication Critical patent/MXPA05006042A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion proporciona poblaciones de celulas que comprenden celulas dendriticas parcialmente maduras que pueden ser utilizadas para administrase a personas que tienen un tumor. Las celulas dendriticas parcialmente maduradas, aquellas que estan en contacto con un agente de maduracion dendritico durante aproximadamente 1 a aproximadamente 10 horas o mas, captan y procesan eficientemente los antigenos tumorales en el area del sitio del tumor, maduracion completa, y posteriormente, pueden migrar a los ganglios linfaticos de un individuo tratado. Una vez en el ganglio linfatico, el antigeno ahora completamente maduro que presenta celulas dendriticas, secreta las citocinas apropiadas (e.g., TNF( e IL-12) y contacta las celulas T que inducen una respuesta inmune sustancialmente anti-tumoral.
MXPA05006042A 2002-12-06 2003-12-05 Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores. MXPA05006042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (1)

Publication Number Publication Date
MXPA05006042A true MXPA05006042A (es) 2005-09-21

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006042A MXPA05006042A (es) 2002-12-06 2003-12-05 Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.

Country Status (19)

Country Link
US (2) US20060057120A1 (es)
EP (2) EP2260861A1 (es)
JP (2) JP4859169B2 (es)
KR (1) KR101144196B1 (es)
CN (2) CN102600461B (es)
AT (1) ATE486125T1 (es)
AU (2) AU2003293411B2 (es)
BR (1) BRPI0317064B8 (es)
CA (1) CA2509058A1 (es)
DE (1) DE60334725D1 (es)
DK (1) DK1567155T3 (es)
ES (1) ES2354944T3 (es)
HK (1) HK1082180A1 (es)
IL (1) IL169002A (es)
MX (1) MXPA05006042A (es)
PL (1) PL377209A1 (es)
PT (1) PT1567155E (es)
RU (1) RU2348418C2 (es)
WO (1) WO2004053072A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006042A (es) * 2002-12-06 2005-09-21 Northwest Biotherapeutics Inc Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
WO2009120891A2 (en) 2008-03-27 2009-10-01 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
DK2451943T3 (en) * 2009-07-09 2017-02-06 Tigenix S A U METHODS AND COMPOSITIONS FOR USE IN CELL THERAPIES
HUE028352T2 (en) * 2010-02-10 2016-12-28 Immunicum Ab An improved composition for inhibiting tumor cell proliferation
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
JP6985939B2 (ja) * 2015-06-30 2021-12-22 ノースウエスト バイオセラピューティクス，インコーポレイティド 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞
CN116413420A (zh) * 2015-09-15 2023-07-11 西北生物治疗药物公司 涉及用于患有晚期癌症的受试者的经活化树突状细胞组合物和免疫治疗处理的方法
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
AU6144499A (en) * 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
KR20020013470A (ko) * 1998-10-02 2002-02-20 미우라 아키라 세포성 면역의 유도방법 및 세포성 면역이 유도된 세포
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
BR0009772A (pt) * 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
US20030108527A1 (en) * 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
PL372098A1 (en) * 2001-09-06 2005-07-11 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
MXPA05006042A (es) * 2002-12-06 2005-09-21 Northwest Biotherapeutics Inc Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
KR101201875B1 (ko) * 2003-02-27 2012-11-15 노쓰웨스트 바이오써라퓨틱스, 인크. 부가의 사이토킨의 부재하에 ｇｍ-ｃｓｆ를 사용한 단핵구수지상 전구체 세포로부터의 수지상 세포 생성방법

Also Published As

Publication number Publication date
DK1567155T3 (da) 2011-02-14
JP2011246493A (ja) 2011-12-08
KR101144196B1 (ko) 2012-05-21
JP2006510667A (ja) 2006-03-30
KR20050084189A (ko) 2005-08-26
JP5707284B2 (ja) 2015-04-30
ES2354944T3 (es) 2011-03-21
IL169002A (en) 2015-01-29
CN1738619A (zh) 2006-02-22
CN102600461B (zh) 2017-07-14
US20120251561A1 (en) 2012-10-04
BR0317064A (pt) 2005-10-25
BRPI0317064B8 (pt) 2021-05-25
RU2005121256A (ru) 2006-02-10
ATE486125T1 (de) 2010-11-15
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
WO2004053072A2 (en) 2004-06-24
RU2348418C2 (ru) 2009-03-10
BRPI0317064B1 (pt) 2020-11-03
AU2011200352B2 (en) 2013-06-27
CA2509058A1 (en) 2004-06-24
EP1567155B1 (en) 2010-10-27
AU2011200352A1 (en) 2011-02-17
AU2003293411A1 (en) 2004-06-30
CN102600461A (zh) 2012-07-25
US20060057120A1 (en) 2006-03-16
JP4859169B2 (ja) 2012-01-25
EP2260861A1 (en) 2010-12-15
WO2004053072A3 (en) 2005-06-16
HK1082180A1 (en) 2006-06-02
PT1567155E (pt) 2011-01-28
PL377209A1 (pl) 2006-01-23
AU2003293411B2 (en) 2010-10-28
DE60334725D1 (de) 2010-12-09
EP1567155A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
HK1082180A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Okamoto et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
Libraty et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
Shibaki et al. Induction of skewed Th1/Th2 T‐cell differentiation via subcutaneous immunization with Freund's adjuvant
Leite‐De‐Moraes et al. IL‐4‐producing NK T cells are biased towards IFN‐γ production by IL‐12. Influence of the microenvironment on the functional capacities of NK T cells
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Handel-Fernandez et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice.
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
Conti et al. Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
Sato et al. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK‐432 combined with prostaglandin E2
ZA200401842B (en) Process for the maturation of dentritic cells and a vaccine.
To et al. Therapeutic Efficacy of Th1 and Th2 L‐selectin− CD4+ Tumor‐Reactive T Cells
Mazzoccoli et al. Immune system alterations in lung cancer patients
Zeng et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone‐rich cell lysate vaccination
Valaperti et al. Vaccination with Flt3L-induced CD8α+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis
DK1509244T3 (da) Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine
Holzer et al. Haptens as drugs: contact allergens are powerful topical immunomodulators
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
Karsten et al. Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells

Legal Events

Date Code Title Description
FG Grant or registration